Compare Cytokinetics Inc (CYTK) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs TotalEnergies SE — how do they compare? Cytokinetics Inc trades at $62.72 (market cap $8.62B), while TotalEnergies SE trades at $86.12 (market cap $191.82B). The key difference: TotalEnergies SE is far larger — about 22.3× Cytokinetics Inc's market cap, and TotalEnergies SE pays a 4.93% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and TotalEnergies SE for 90 Days on average.
| CYTK | TTE | |
|---|---|---|
Market Cap | $8.62B | $191.82B |
Volume | 2,594,626 | 3,311,339 |
Sector | Health | Energy |
52-Week High | $87.26 | $93.60 |
52-Week Low | $54.76 | $57.39 |
Typical Hold Time | 19 Days | 90 Days |
Enterprise Value | $8.72B | $222.81B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
TotalEnergies (TTE) trades at $87.25, up 3.59% today, with a bearish technical signal but strong fundamentals including a low P/E of 10.77 and robust cash flow. Recent earnings beat expectations in Q1 and Q2 2026, while the company announced a $10 billion investment in Argentina and plans for dividend growth through 2030, signaling strategic expansion.
The outlook is positive with analyst consensus at Buy and a $95.33 price target, though risks include declining revenue trends and geopolitical exposure. Upside potential hinges on execution of growth initiatives and energy price stability, while investor sentiment remains supported by shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
